drugset / Trial / NCT00417248
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
Phase 1/2
Terminated
8 enrolled
Nasser Hanna, M.D.
Amgen · collabBayer · collabWalther Cancer Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
Sorafenib has demonstrated in vivo anti-tumor efficacy. This trial will evaluate the safety and preliminary efficacy of sorafenib following chemoradiation in locally advanced NSCLC.
Timeline
- Start
- 2007-06
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | Oral |
| Background | Cisplatin | Other / unclassified | 50 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 50 mg/m2 | Intravenous |